ADHERENCE AND PERSISTENCE OF PCSK9 INHIBITORS IN CLINICAL PRACTICE: THE REAL-WORLD ITALIAN EXPERIENCE (AT-TARGET-IT STUDY)

被引：0
|
作者：
Marzano, Federica [1 ]
Basile, Christian [2 ]
Paolillo, Stefania [2 ]
Cesaro, Arturo [3 ]
Buonocore, Davide [2 ]
Asile, Gaetano [2 ]
Abbate, Vincenza [2 ]
Vicidomini, Francesca [2 ]
Spaccarotella, Carmen Anna Maria [2 ]
Spirito, Giulio [4 ]
Maloberti, Alessandro [5 ,6 ]
Iannuzzo, Gabriella [7 ]
Ciccone, Marco Matteo [8 ]
D'alleva, Alberto [9 ]
Corleto, Antonella [10 ]
Brunetti, Natale Daniele [11 ]
Indolfi, Ciro [12 ]
Gargiulo, Paola [2 ]
Perrone-filardi, Pasquale [2 ]
机构：
[1] IRCCS Synlab Sdn, Naples, Italy
[2] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy
[3] Univ Campania Luigi Vanvitelli, Dept Translat Med Sci, Caserta, CE, Italy
[4] Eboli Battipaglia Roccadaspide Maria Ss Addolorat, Emergency Dept, Div Cardiol, Eboli, Italy
[5] Asst Gom Niguarda, Div Cardiol 4, Cardioctr De Gasperi, Milan, Italy
[6] Bicocca Univ, Milan, Italy
[7] Univ Naples Federico II, Dept Clin Med & Surg, Naples, Italy
[8] Univ Bari, Sch Cardiol, Bari, Italy
[9] Santo Spirito Hosp, Ccu Intervent Cardiol, Pescara, Italy
[10] Asl Torino 3, Rivoli Infermi Hosp, Turin, Italy
[11] Policlin Riuniti Univ Hosp, Cardiothorac Dept, Foggia, Italy
[12] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Catanzaro, Italy
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2022年 / 24卷
关键词：
D O I：
10.1093/eurheartjsupp/suac121.706
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
555
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-world effectiveness of monoclonal antibody inhibitors of PCSK9 in patients with heterozygous familial hypercholesterolemia: A retrospective cohort study
    Siemens, Rebecca
    Pryjma, Mark
    Buchkowsky, Susan
    Barry, Arden R.
    PHARMACOTHERAPY, 2024, 44 (09): : 730 - 737
  • [42] PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
    Ferrari, Filipe
    Stein, Ricardo
    Motta, Marcelo Trotte
    Moriguchi, Emilio Hideyuki
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2019, 112 (04) : 453 - 460
  • [43] PCSK9 inhibitors. New treatment option in clinical practice
    Mueller-Wieland, D.
    Marx, N.
    HERZ, 2016, 41 (04) : 290 - 295
  • [44] PCSK9 inhibitors in clinical practice: Novel directions and new experiences
    Rallidis, Loukianos S.
    Skoumas, Ioannis
    Liberopoulos, Evangelos N.
    Vlachopoulos, Charalambos
    Kiouri, Estela
    Koutagiar, Iosif
    Anastasiou, Georgia
    Kosmas, Nikolaos
    Elisaf, Moses S.
    Tousoulis, Dimitrios
    Iliodromitis, Efstathios
    HELLENIC JOURNAL OF CARDIOLOGY, 2020, 61 (04) : 241 - 245
  • [45] IMPROVING PROGNOSIS OF HCC IN THE REAL-WORLD CLINICAL PRACTICE: AN ITALIAN EXPERIENCE
    Borzio, M.
    Sacco, R.
    Fanigliulo, L.
    Parisi, G.
    Francica, G.
    Dionigi, E.
    Salvagnini, M.
    Di Fonzo, M.
    Salmi, A.
    De Sio, I.
    Vicari, S.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S108 - S108
  • [46] Initial Real-World Experience With PCSK-9 Inhibitors in Current Indications for Reimbursement in Spain
    Cordero, Alberto
    Facila, Lorenzo
    Rodriguez-Manero, Moises
    Gomez-Martinez, Manuel J.
    Bertomeu-Martinez, Vicente
    Gonzalez-Juanatey, Jose R.
    REVISTA ESPANOLA DE CARDIOLOGIA, 2019, 72 (11): : 968 - 970
  • [47] Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom
    Tai, Ming-Hui
    Shepherd, Jason
    Bailey, Hollie
    Williams, Nathan
    Hatz, Maximilian
    Tapias, Ignasi Campos
    Catterick, David
    Worth, Gavin
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (05) : 829 - 835
  • [48] Number of Patients Eligible for PCSK9 Inhibitors Based on Real-world Data From 2.5 Million Patients
    Zamora, Alberto
    Masana, Luis
    Comas-Cufi, Marc
    Plana, Nuria
    Vila, Alex
    Garcia-Gil, Maria
    Alves-Cabratosa, Lia
    Elosua, Roberto
    Marrugat, Jaume
    Ramos, Rafel
    REVISTA ESPANOLA DE CARDIOLOGIA, 2018, 71 (12): : 1010 - 1017
  • [49] Real-world lipid lowering effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: A single-centre study
    Han, J.
    Bilgrami, S.
    Ross, S.
    Broadhead, H.
    Attar, N.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 322 : 240 - 244
  • [50] Efficacy and safety of PCSK9-Inhibitors in the real-world: data from a clinical registry
    Saba, P. S.
    Murgia, A.
    Gazale, E.
    Terrosu, P.
    Sanna, G. D.
    Parodi, G.
    EUROPEAN HEART JOURNAL, 2020, 41 : 3338 - 3338
12345